Stock News and Filings Feed
A Pfizer flag is displayed in front of the company's world headquarters in New York on Monday, Nov. 23, 2015. (AP / Mark Lennihan)
(Reuters) - The U.S. Food and Drug Administration (FDA) said on Thursday it approved Pfizer Inc's rare blood cancer drug, Besponsa, with a boxed warning.
Aug 17 (Reuters) - The U.S. Food and Drug Administration (FDA) said on Thursday it approved Pfizer Inc's treatment for a rare type of blood cancer.
We have a set of stocks in our watchlist that do not have a product in the market and are yet valued at over a billion dollars each in terms of market capitalization. Topping the list are Kite Pharma (KITE) and bluebird bio (BLUE), which are valued that high because they are pioneering CAR-T therapy. There are 29 more stocks in our list, of which, at least one, Opko Health (OPK), does have marketed products, although we have still put it up in that list because we believe its value comes more from its chairman, Dr.
This article is part of a series that provides an ongoing analysis of the changes made to David Tepper’s US stock portfolio on a quarterly basis. It is based on Appaloosa Management’s regulatory 13F Form filed on 08/14/2017. Please visit our Tracking David Tepper’s Appaloosa Management Portfolio series to get an idea of his investment philosophy and our previous update for the fund’s moves during Q1 2017.
With the general market all over the place in recent weeks, dropping and climbing seemingly on a whim, I am reminded, once again, that finding the "perfect" time to invest is a fool's game. Seeing the market behave in this manner simply reminds me to keep making my monthly buys, ignoring the noise and predictions and simply holding on if the "ride" gets a little wild. When you think about it, as long-term dividend growth investors, that's really all we can do.
Bristol-Myers Squibb Company (BMY - Free Report) announced disappointing top-line results from the CheckMate-214 trial. The study investigated immuno-oncology drug Opdivo (nivolumab) in combination with Yervoy (ipilimumab) versus Pfizer Inc.’s (PFE) Sutent in intermediate and poor-risk patients previously untreated advanced or metastatic renal cell carcinoma.
New York: Big-name drugmakers want to profit from selling lower-priced copies of rivals’ expensive biotechnology drugs. Patients and doctors want to pay less for medicine.
We issued an updated research report on Boulder, CO-based Clovis Oncology, Inc. (CLVS - Free Report) on Aug 14.
Fairfax Financial’s largest five 13F stakes are BlackBerry, Kennedy Wilson, Resolute Forest Products, International Business Machines, and USG. They together account for ~87% of the US long assets.
NEW YORK, Aug. 11, 2017 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Tableau Software, Inc. ("Tableau" or the "Company") (NYSE: DATA) and certain of its officers. The class action, filed in United States District Court, Western District of Washington, Seattle Division, and docketed under 17-cv-01175, is on behalf of a class consisting of investors who purchased or otherwise acquired Tableau securities, seeking to recover compensable damages caused by defendants' violations of the Securities Exchange Act of 1934.
NEW YORK, Aug. 10, 2017 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of DENTSPLY SIRONA Inc. ("Dentsply" or the "Company") (NASDAQ: XRAY). Such investors are advised to contact Robert S. Willoughby at email@example.com or 888-476-6529, Ext. 9980.
NEW YORK, Aug. 10, 2017 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Pfizer Inc. ("Pfizer" or the "Company") (NYSE: PFE). Such investors are advised to contact Robert S. Willoughby at firstname.lastname@example.org or 888-476-6529, Ext. 9980.
- PD-1 Refractory Melanoma Cohort of ENCORE 601 Completes Enrollment - - First Patient Dosed in ENCORE 601 Colorectal Cancer Cohort - -Company to Host Conference Call Today at 4:30 p.m. ET-
Pharmaceutical companies usually are involved in a lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study come back negative or a candidate not be approved. Conversely, if a drug gains FDA approval or passes a clinical trial, there can be big upside.
Well that didn’t take long. Just a few days into the month of August, I already made my first purchases. With the start of the new month we have seen a couple of notable stocks plummeting in a single day, highlighting the knee jerk reactions investors make when earnings or guidance does not paint a growing and rosy picture. First we have seen Cardinal Health, Inc. (NYSE:CAH) take it on the chin after announcing downbeat guidance for 2018, and fellow peer AmerisourceBergen Corporation (NYSE:ABC), while showing an earnings beat, dropped approximately 13% on a sales miss.
Indian ADRs ended with mixed sentiments in the market during the trading hours of August 9.
Nifty closed at 9,908, down by 70 points while Sensex closed at 31,797, down by 216 points on Wednesday.
Disclaimer: The contents herein is specifically prepared by ‘Dalal Street Investment Journal’, and is for your information & personal consumption only. India Infoline Limited or Dalal Street Investment Journal do not guarantee the accuracy, correctness, completeness or reliability of information contained herein and shall not be held responsible.
Equities in Asia were trading mixed in Thursday’s trade, although geopolitical tensions continue to weigh on the Asian equities.
Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services.
MEXICO CITY (Reuters) - Major drugmakers including GlaxoSmithKline Plc, Pfizer Inc and Sanofi SA use legal ways to stifle competition in Mexico from generics that are readily available elsewhere, a senior Mexican antitrust official said on Wednesday.
SEATTLE, WA--(Marketwired - Aug 9, 2017) - CFN Media Group ("CannabisFN"), the leading creative agency and digital media network dedicated to legal cannabis, announces the publication of an article discussing Future Farm Technologies Inc. (CSE: FFT) (OTCQB: FFRMF) and featuring an exclusive video shot on site at the company's cannabis extraction facility in Los Angeles.
The portfolio continues to be very concentrated with the top five positions accounting for ~43% of the 13F holdings.
Horizon Pharma plc (HZNP - Free Report) topped both earnings and sales estimate in second-quarter 2017. The company also raised its sales guidance for 2017. The company’s shares moved up 4.72% on better-than-expected second-quarter results and increased guidance.